Third time's the charm: Adamis nabs ap­proval of high-dose nalox­one in­jec­tion af­ter two CRLs

If at first you don’t suc­ceed, and at sec­ond you don’t suc­ceed, try, try again.

That’s been the un­of­fi­cial mantra for Adamis Phar­ma­ceu­ti­cals’ high dose nalox­one in­jec­tion, which re­ceived two CRLs in the span of a year be­tween the No­vem­bers of 2019 and 2020. But on Mon­day, word came through that the FDA ap­proved the drug on Adamis’ third at­tempt, giv­ing doc­tors an­oth­er tool to treat in­di­vid­u­als who over­dose on opi­oids.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.